Autopsy report · NCT02974426

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

“Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 years 3 months before it stopped.
• 132 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Shanghai Chest Hospital

Sponsor type

University, hospital or other

Conditions

Non-small Cell Lung Cancer Stage IIIA; Radiotherapy

Interventions

PORT-first; PORT-last; Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

Participants

132

Sites

1

Countries

China

Trials that died the same way

• Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
  “Clinical trial was halted prematurely due to low enrollment” (71% match in meaning)
• Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
  “Closed to accrual to allow enrollment on another more promising trial.” (70% match in meaning)
• ODEN Trial: Option vs. Denali IVC Filters
  “ODEN trial stopped due to low enrollment \& to focus on the PRESERVE Trial.” (68% match in meaning)
• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
  “Trial has been cancelled due to availability of new therapeutic options for patient population” (68% match in meaning)
• A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
  “The decision was made to prematurely discontinue this trial due to lack of efficacy.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.